BR112022016359A2 - Formas cristalinas de um composto farmacêutico - Google Patents
Formas cristalinas de um composto farmacêuticoInfo
- Publication number
- BR112022016359A2 BR112022016359A2 BR112022016359A BR112022016359A BR112022016359A2 BR 112022016359 A2 BR112022016359 A2 BR 112022016359A2 BR 112022016359 A BR112022016359 A BR 112022016359A BR 112022016359 A BR112022016359 A BR 112022016359A BR 112022016359 A2 BR112022016359 A2 BR 112022016359A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline forms
- pharmaceutical compound
- compound
- pharmaceutical
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005114.0A GB202005114D0 (en) | 2020-04-07 | 2020-04-07 | Crystalline Forms of a Pharmaceutical Compound |
| PCT/EP2021/058864 WO2021204762A1 (en) | 2020-04-07 | 2021-04-06 | Crystalline forms of a tyk2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022016359A2 true BR112022016359A2 (pt) | 2022-10-04 |
Family
ID=70768933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016359A BR112022016359A2 (pt) | 2020-04-07 | 2021-04-06 | Formas cristalinas de um composto farmacêutico |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12545652B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4132649A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7660135B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220164751A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115515683B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022016359A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3167172A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB202005114D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296989A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011593A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021204762A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
| JP2025510826A (ja) * | 2022-03-25 | 2025-04-15 | 武田薬品工業株式会社 | Tyk2阻害剤の固体形態及び使用方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794096A (fr) | 1972-08-07 | 1973-05-16 | Lepetit Spa | Oxazoles 2,4,5-trisubstitues et leur preparation |
| GB1497536A (en) | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
| JPH0753716B2 (ja) | 1986-07-02 | 1995-06-07 | 吉富製薬株式会社 | イミダゾ−ルカルボキサミド誘導体 |
| DE19653355A1 (de) | 1996-12-20 | 1998-06-25 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung |
| GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| BR0111754A (pt) | 2000-06-28 | 2003-04-29 | Astrazeneca Ab | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica |
| AU2479702A (en) | 2000-10-30 | 2002-05-15 | Janssen Pharmaceutica Nv | Tripeptidyl peptidase inhibitors |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| ATE465731T1 (de) | 2003-10-23 | 2010-05-15 | Ab Science | 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer |
| GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| CA2623327A1 (en) | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| WO2007131953A1 (en) | 2006-05-12 | 2007-11-22 | Ab Science | A new process for the synthesis of 2-aminoxazole compounds |
| US20090093452A1 (en) | 2006-08-24 | 2009-04-09 | Pfizer Inc. | Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| US8367706B2 (en) | 2007-06-20 | 2013-02-05 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2278969B1 (en) | 2008-04-21 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| EP2299816B1 (en) | 2008-06-18 | 2013-11-13 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2310384B1 (en) | 2008-07-09 | 2014-04-09 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2166006A1 (en) | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| US20130096104A1 (en) | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| US20130143915A1 (en) | 2010-07-01 | 2013-06-06 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| SG11201401342VA (en) | 2011-10-12 | 2014-09-26 | Array Biopharma Inc | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| ES2566205T3 (es) | 2012-03-02 | 2016-04-11 | Sareum Limited | Inhibidores de quinasa TYK2 |
| KR101202026B1 (ko) | 2012-07-03 | 2012-11-16 | 민호현 | 황토 석부작 제조 방법 |
| HRP20220766T1 (hr) | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| BR112016004723B1 (pt) * | 2013-09-03 | 2022-08-30 | Sareum Limited | Compostos de pirrolidina ou morfolina e composição contendo os mesmos |
| NO2721710T3 (cg-RX-API-DMAC7.html) | 2014-08-21 | 2018-03-31 | ||
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
-
2020
- 2020-04-07 GB GBGB2005114.0A patent/GB202005114D0/en not_active Ceased
-
2021
- 2021-04-06 IL IL296989A patent/IL296989A/en unknown
- 2021-04-06 BR BR112022016359A patent/BR112022016359A2/pt unknown
- 2021-04-06 MX MX2022011593A patent/MX2022011593A/es unknown
- 2021-04-06 WO PCT/EP2021/058864 patent/WO2021204762A1/en not_active Ceased
- 2021-04-06 JP JP2022559959A patent/JP7660135B2/ja active Active
- 2021-04-06 EP EP21717041.4A patent/EP4132649A1/en active Pending
- 2021-04-06 US US17/905,183 patent/US12545652B2/en active Active
- 2021-04-06 CN CN202180025999.3A patent/CN115515683B/zh active Active
- 2021-04-06 KR KR1020227038120A patent/KR20220164751A/ko active Pending
- 2021-04-06 CA CA3167172A patent/CA3167172A1/en active Pending
-
2026
- 2026-01-06 US US19/440,870 patent/US20260217664A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021253128A1 (en) | 2022-08-25 |
| GB202005114D0 (en) | 2020-05-20 |
| KR20220164751A (ko) | 2022-12-13 |
| JP7660135B2 (ja) | 2025-04-10 |
| EP4132649A1 (en) | 2023-02-15 |
| MX2022011593A (es) | 2022-10-18 |
| CA3167172A1 (en) | 2021-10-14 |
| US20230159473A1 (en) | 2023-05-25 |
| IL296989A (en) | 2022-12-01 |
| CN115515683A (zh) | 2022-12-23 |
| WO2021204762A1 (en) | 2021-10-14 |
| CN115515683B (zh) | 2024-10-25 |
| US20260217664A1 (en) | 2026-07-30 |
| US12545652B2 (en) | 2026-02-10 |
| JP2023521631A (ja) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| CL2022000027A1 (es) | Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257). | |
| CL2022003528A1 (es) | Formas cristalinas novedosas (divisional de cl 202002056). | |
| MX2021001433A (es) | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa. | |
| DOP2020000023A (es) | Nuevos derivados de quinolina | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| CO2020013876A2 (es) | Nuevos derivados de quinolina | |
| CO2023013469A2 (es) | Derivados de fósforo como nuevos inhibidores de sos1 | |
| UY38716A (es) | Derivados de isoxazolina herbicidamente activos, y procesos e intermediarios utilizados para la preparación de estos derivados | |
| BR112022001125A2 (pt) | Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos | |
| CL2021001753A1 (es) | Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253). | |
| CR20240408A (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2. | |
| MX2021010869A (es) | Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso. | |
| CO2021014260A2 (es) | Formas sólidas de un inhibidor de glyt1 | |
| ECSP22040921A (es) | Composición farmacéutica que comprende selexipag | |
| MX2022005522A (es) | Formas de sal de un receptor de componente c5a de complemento. | |
| ECSP034598A (es) | Compuesto lactamico | |
| CL2024002379A1 (es) | Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso | |
| ECSP22046595A (es) | Procesos e intermediario para la preparaci?n de oxetan-2-ilmetanamina | |
| BRPI0406824A (pt) | Indolonaoxazoldinonas antiibacterianas, intermediários para seu preparo e composições farmacêuticas que as contêm | |
| AR114270A1 (es) | Compuestos de 4-metildihidropirimidinona y su uso farmacéutico | |
| MX2022011593A (es) | Formas cristalinas de un compuesto farmaceutico. | |
| CL2021002501A1 (es) | Compuestos novedosos y métodos de uso de los mismos. | |
| CL2022001658A1 (es) | Derivado de amino arilo novedoso útil como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo. | |
| MX2021004647A (es) | Formas cristalinas de moduladores de los canales de potasio. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |